PARP Inhibitor Combination Shows Activity in Small Cell Lung Cancer - Cancer Therapy Advisor

PARP Inhibitor Combination Shows Activity in Small Cell Lung Cancer  Cancer Therapy Advisor

Olaparib plus temozolomide appeared safe and active in relapsed small cell lung cancer, according to the results of a single-arm phase 1/2 trial.



Comments

Popular posts from this blog

Oncology: The disease, dynamics & challenges of market research

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Lung Cancer Among People Who Never Smoked